Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02548728 · ClinicalTrials.gov registry record · Phase 1

Oxytocin Treatment of Opioid Dependence

A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT02548728 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02548728, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

Purpose: The purpose of this research study is to learn whether oxytocin treatment decreases use of and cravings for opioids (narcotics) in people who have been using opioids heavily for long periods of time and are unable to stop on their own. Participants: Patients meeting DSM-IV-TR criteria for opioid dependence. Procedures (methods): Subjects will have standard medications available for withdrawal symptoms from opioids and standard psychosocial interventions available in the inpatient setting. In addition, subjects will self-administer intranasal test treatments 3 times daily.

Interventions

  • DRUG Placebo
  • DRUG Intranasal Oxytocin Spray

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2016-02
Est. Completion 2016-12
Phase Phase 1

What the Registry Record Tells You About NCT02548728

The ClinicalTrials.gov registry entry for NCT02548728 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02548728 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02548728 about?

NCT02548728 is a clinical study titled "Oxytocin Treatment of Opioid Dependence". Purpose: The purpose of this research study is to learn whether oxytocin treatment decreases use of and cravings for opioids (narcotics) in people who have been using opioids heavily for long periods of time and are unable to stop on their own. Participants: Patients meeting DSM-IV-TR criteria for ...

What is the current status of trial NCT02548728?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-02. Estimated completion is 2016-12.

What interventions are being tested in trial NCT02548728?

The interventions under investigation include: Placebo (DRUG), Intranasal Oxytocin Spray (DRUG).

Who is sponsoring clinical trial NCT02548728?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.